MTN-027 Screening Visit Procedures. SSP Manual References Protocol Section 7.2 and Table 10 (Screening) Section 4: Study Procedures Section 5: Informed.

Slides:



Advertisements
Similar presentations
1 MTN-003 Training Follow-up Visit Scheduling and Visit Coding SSP Sections and
Advertisements

Overview of Follow-up Visit Types and Visit Scheduling Training Binder Tab: Follow-up Visits.
Every Womans Life PROGRAM MANUAL UPDATE
Tips to a Successful Monitoring Visit
ASPIRE Off-Site Visits. Rationale Why make an allowance for off-site visits in the protocol? Adherence & Retention Off-site visits Improving Clinic Flow.
HIV Counseling &Testing. Page 346 HIV and Risk Reduction (RR) Counseling Required at all scheduled visits Includes HIV Pre- and Post-test counseling.
1 MTN-003 Study Specific Training Randomization Overview.
ASPIRE TRAINING RANDOMIZATION & INITIAL DISPENSING Cindy Jacobson, PharmD (MTN) Jen Berthiaume/Missy Cianciola (SCHARP)
Reportable AEs – Report on AE Log CRF
CTR Form B: Testing Information. Overview: Form B collects information about the testing and counseling services provided to a client. It is intended.
G ENITAL B LEEDING ASPIRE SSP Section Updates 31 January 2014.
Study Product Adherence Counseling At Follow-up Visits
1 MTN-003 Training Specimen Labeling and Preparation for Entry into LDMS.
Contraception/Pregnancies MTN 020. Why do we care? Participants must come off product during pregnancy and breastfeeding – Studies of dapivirine in pregnant.
Contraception Counseling Considerations MTN-003 Study-Specific Training.
Baseline Medical and Menstrual History The ins, outs, ups, and downs of collecting a relevant and complete baseline medical/menstrual history MTN 020 Training.
Genital Bleeding MTN 020 Training. Background  Genital Bleeding is common Includes menses Includes intermenstrual bleeding (IMB)  Determining whether.
Nurse Practitioner Data Log: Student-Patient Computer Data Log Form The University of Michigan School of Nursing.
1 MTN-003 Training General Interviewing Techniques Some specific tips for administering the Screening interviewer-administered CRFs SSP Section 14.
1 MTN 003 Data Management Considerations SSP Sections 14, 15 & 17.
ASPIRE TRAINING Study Product Considerations & Accountability for Non-Pharmacy Staff.
MTN-028 Enrollment Visit Procedures Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176)
SSP Manual Update 31 January 2014 Version 1.3 Overview of changes which affect implementation.
Product Use Management MTN 020 Training. Objectives- study product tab  Identify the conditions that would require a product hold or discontinuation.
MTN-028 Laboratory Training May Beamer, Lorna Rabe MTN Laboratory Center Magee-Womens Research Institute Pittsburgh, PA.
Overview of Enrollment Procedures. Training Materials for this session  All materials for this session can be found under the Enrollment tab of your.
MTN-027 Laboratory Related CRFs. Pharmacokinetics Specimens (PKS-1) - Enrollment, Day 28 Pharmacokinetics Specimens (PKD-1) - Days 1, 2, 3, 7, 14, 21,
SMART Study Closeout Washington ICC Meeting 03 June 2007.
AE/SAE/EAE Identification and Reporting AE/SAE/EAE Identification and Reporting.
Follow-up Visit Procedures MTN-028 Study Specific Training.
Informed Consent Process: Key Considerations. Introduction  Informed consent is a requirement of ethical clinical research  Section 4.8 of the International.
Cluster Interview Template Updated 04/2013. Introduction to the Training ● The slides will first show a picture of the section of the template that will.
Improving Eligibility Documents November, Improving Data Collection The State Office of AIDS (OA) is now working with providers to improve the quality.
MTN-027 Clinical Management CRFs. CRFs for Clinical Management Physical Exam Pelvic Exam Diagrams Pelvic Exam Pelvic Exam Ring Assessment Clinical Product.
Investigator’s Meeting
Comprehensive Field Record. Introduction to the Training ● The slides will first show a picture of the section of the template that will be discussed.
Secaucus Reflect Live Observation Process Observer Guide.
Comprehensive Field Record. Introduction to the Training ● The slides will first show a picture of the section of the template that will be discussed.
Informed Consent. Types of Informed Consent  Screening  Enrollment  Off-site visits  Specimen storage  In depth interviews/focus groups.
**INSERT YOUR TITLE HERE**
Protocol Deviations. MTN protocol deviation policy  MTN has recently revised their policy on PDs- this policy will be made available on the MTN website.
MTN-028 Laboratory Related CRFs. Pharmacokinetics Specimens (PKS-1) - Enrollment, Day 28 Pharmacokinetics Specimens (PKD-1) - Days 1, 2, 3, 7, 14, 21,
Baseline Medical and Menstrual History The ins, outs, ups, and downs of collecting a relevant and complete baseline medical/menstrual history MTN 020 Training.
MTN-025/HOPE Decliner Population Procedures. Who are the Decliner Population? Former ASPIRE participants who decline or express no interest in joining.
Protocol Requirements for Product Holds/Discontinuations MTN-025.
Overview of Key Clinical Considerations MTN 025 Training.
Overview of Screening Visit Procedures, PTID Assignment, Screening & Enrolment Logs, and Screen Failures Objectives: Review screening visit procedures.
Informed Consent Objectives: Review – Types of informed consent
Planning for HOPE PUEVs and Study Exit Visits
Overview of Visit Scheduling and Types of Follow-up Visits SCHARP
Management of Pregnancies
30 April 2015 Updated 29 December 2015
Off-Site Visit Procedures and Documentation Considerations
Field Inventory Services-Sanofi Inventory and Audit Training
MTN-036 Study of Extended Duration Dapivirine Vaginal Ring for HIV Prevention How do I know if I’m Eligible to join? Women who join the study must.
MTN-025 Data Communiqué #1 CRF Updates.
Protocol References Section Title 6.2 Entry Visit 5.1
HOPE STUDY PRODUCT TRAINING PHASE 2
Protocol References Section Title 6.2 Entry Visit 5.1
IMPAACT 2010 Screening Visits
MTN-037 Training Julie Ngo SCHARP April 12, 2018.
MTN-037 Screening and Enrollment
Follow-up Visit Considerations
Overview of Enrollment Procedures
MTN-020 Common QCs and Form Completion Questions
HIV Counseling.
Administering Behavioral CRFs
MTN-037 Protocol Overview
Participant Retention
E-CRF Overview Oracle® Clinical Remote Data Capture Training (Version 4.6 HTML) e-CRF Completion John McDonach Manager CDM, PPD.
Presentation transcript:

MTN-027 Screening Visit Procedures

SSP Manual References Protocol Section 7.2 and Table 10 (Screening) Section 4: Study Procedures Section 5: Informed Consent Section 9: Laboratory Considerations Section 10: Counseling Considerations

Screening Visit Components Administrative IC Administration Comprehension Assessment PTID Assignment Demographic Information Eligibility Assessment Reimbursement Provision Next Visit Scheduling* Counseling HIV Pre-and Post Test HIV Risk Reduction Contraceptive Protocol Adherence Clinical Physical Exam Pelvic Exam Medical/Menstrual History Review Medication History Review Referrals or Rx for UTIs/RTIs/STIs* Provision of Available Results * If indicated

Screening Visit Components (Cont’d) Urine hCG (pregnancy) Dipstick UA Urine Culture* Blood CBC with differentials/platelets HIV-1 Serology Hepatitis B Surface Antigen Hepatitis C Antibody Syphilis Serology Chemistries (ALT/AST/Creatinine) Coagulation (INR) Genital Rapid Trichomonas Test NAAT for GC/CT Vaginal pH* KOH Wet Mount for Candidiasis* Saline Wet Mount for BV* Pap Test* * If clinically indicated

Informed Consent Tools

Informed Consent Form Required ScreeningEnrollmentIn-Depth Interview Optional Rectal FluidSpecimen Storage

Consent for Participation in In-Depth Interview

Consent for Participation in Extra Samples Group (Rectal Fluid Subset)

Consent for Long-Term Specimen Storage and Future Testing

Informed Consent Coversheet Captures all required elements of IC documentation Use of a coversheet strongly recommended

Administered after IC discussion but before the participant signs the ICF Assists staff in assessing participant comprehension and ensures participant understanding prior to providing consent for study participation Comprehensi on Assessment

Sample Vaginal Ring Information Booklet Calendar with study visit schedule Urine specimen cup Blood collection tubes IVR Insertion Instructions Other randomization explanation visual aids (e.g., sack or box containing four items of different colors) Visual Aids

Eligibility Assessment

Eligibility Determination All eligibility criteria are initially assessed at Screening. All eligibility criteria are confirmed on the day of Enrollment. It is the responsibility of the site Investigator of Record (IoR) and other designated staff to ensure that only participants who meet the study eligibility criteria are enrolled in the study.

Screening Behavioral Eligibility Worksheet Recommended source document for assessing eligibility criteria which are based on self-report

Screening Counseling Tools

Assess eligibility criteria related to pregnancy intentions and willingness to use an effective contraceptive method Focus on explaining which methods are acceptable for study purposes and emphasize that women who cannot commit to use of these methods for the duration of the study should not enroll Contraceptiv e Counseling Worksheet

Overview of the minimum requirements for HIV testing and counseling sessions Assess participant knowledge of relevant information, dispel any misconceptions, ensure participant readiness for HIV testing, ensure participant understanding of test results Guides the participant in identifying risk factors, barriers to risk reduction and developing strategies and action plans to reduce/eliminate risk HIV Pre/Post Test and Risk Reduction Counseling Worksheet

Protocol Adherence Counseling Reference the ‘Prohibited Activities and Products’ section of the MTN- 027 Important Study Information Booklet available on the MTN-027 webpage ( Review the list of prohibited medications, products and practices participants should refrain from engaging in or using during study participation Document provision of counseling in chart notes and/or visit checklist

Protocol Adherence Counseling

Other Visit Tools

Screening Visit Checklist Serves to guide proper study procedures as well as to serve as source documentation of procedures performed at study visits

Screening and Enrollment Log

Enrollment Screening 45 Days  If needed, screening visit procedures can be completed over multiple visits. One rescreen allowed per IoR discretion Screening Window

For example, if a participant signs the informed consent on July 1 st, the last day for enrollment is August 15 th. Since enrollment is considered Day 0, you count backward -45. To make things easier, Last Day to Enroll Calculator was created so sites can enter the screening date and the calculator will provide the last day of enrollment.

Last Day to Enroll Calculator

Required Documentation for Screen Failures Completed ICF Reason(s) for ineligibility, with date of determination, as per the completed Eligibility Checklist Necessary referrals on file (as appropriate) and documentation that any clinically significant abnormalities (labs, etc.) were communicated to the participant (even if referral is not necessary) All source documentation complete up until the time that ineligibility was determined Chart notes complete up until the time ineligibility was determined Indication of what visit procedures were conducted (on visit checklists) Completed Eligibility Criteria CRF, updated with screen failure reason(s) and faxed to DF/Net Completed Screening and Enrollment Log with reason for discontinuation

MTN-027 Screening Visit CRFs

Approach to CRF Training Focus on purpose/reason for key CRFs Will try to address questions received during external review of CRFs Will not go item by item, but will focus on key fields Will not review form instructions, but will refer to these as needed Please ask questions!

Screening CRFs Demographics CRF Eligibility Criteria CRF Pre-existing Conditions CRF Concomitant Medications Log CRF Physical Exam Pelvic Exam CRF (+ pelvic exam diagrams form) Safety Laboratory Results CRF

Demographics (DEM-1) Completed once for each participant at Screening Visit Interviewer-administered Collects required participant descriptors ◦Age ◦Race ◦Ethnicity Collects descriptors requested for publications/reports ◦Gender ◦Highest level education ◦Income Items reflect participant status at Screening only – not updated later unless correction is needed

Pre-existing Conditions Log (PRE) Will include participant-reported conditions as well as abnormalities captured on: ◦Pelvic Exam Diagrams, Pelvic Exam CRFs, (from screening and enrollment) ◦Physical Exam CRFs (from screening and enrollment) ◦Grade 1 and higher laboratory results on Safety Laboratory Results CRF

Pre-existing Conditions log – con’t Page number – start with 01, go up as needed Condition ◦Follow guidelines for AE text except do record past surgeries ◦Be as descriptive as possible Onset Date (Month and Year) ◦If uncertain, use best estimate; year required Comments ◦Add info on frequency and duration of chronic condition outbreaks; other relevant info for the “snapshot”

Pre-existing Conditions log – con’t Ongoing at Enrollment? ◦Leave blank at screening if ongoing; complete at enrollment ◦Chronic/recurrent diagnoses are ongoing Severity Grade ◦Assess per DAIDS Tox Table and FGGT ◦Mark “not gradable” if condition is below Grade 1 or resolved at time of report (ex. Cesarean section entry)

Pre-existing Conditions log– con’t Entries can be added and modified post-enrollment  Participant may have forgotten to report a symptom  Perhaps something that was thought to be not relevant is later considered relevant; if so, add to PRE  May need to collapse signs/symptoms into a diagnosis  Write a chart note to explain why an entry is being added/modified during follow-up Document meds taken for PRE on Concomitant Medications Log CRF

Concomitant Medications Log (CM-1)

Documents meds taken at the time of screening through termination date Complete at Screening; update as needed through termination Record trade name or generic name For vaccines/injections, record separate entry for each dose If exact dose/units not known, put best description possible “Taken for AE” item will always be “no” for entries at Screening Update PRE CRF if CM completion reveals conditions not already reported or observed Concomitant Medications Log (CM-1)

Eligibility Criteria (ECI-1) Allows SCHARP to report on # ppts screened, # enrolled, # screen fails and reasons for screen fails Item 4: Mark all reasons that apply In Screening Visit packet; complete only if screen fail Move to Enrollment Visit packet and complete then if Enrollment scheduled If a participant screen fails, then screens again: Always update and re-fax original ECI completed for the participant - do not complete a 2 nd (new) ECI CRF

Screening Visit QA/QC  Before ppt leaves:  Review visit checklist for completeness  Review screening eligibility checklist/worksheets for completeness  Make sure lab requisition documents are in order  Review pelvic exam/physical exam forms and make sure all needed items are entered on PRE log  Do not fax any forms until ppt enrolls; fax ECI if ppt will not proceed to Enrollment  Make sure systems are in place for enrollment, including scheduling, ppt files, Pharmacy is aware of potential enrollment, etc.

PTID Name Linkage Log MTN-027